Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ProPhase Labs (PRPH) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for ProPhase Labs (PRPH) over the last 15 years, with Q3 2025 value amounting to $41.5 million.

  • ProPhase Labs' Shares Outstanding (Diluted Average) rose 11773.15% to $41.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.5 million, marking a year-over-year increase of 11773.15%. This contributed to the annual value of $20.5 million for FY2024, which is 1892.25% up from last year.
  • ProPhase Labs' Shares Outstanding (Diluted Average) amounted to $41.5 million in Q3 2025, which was up 11773.15% from $41.5 million recorded in Q2 2025.
  • ProPhase Labs' 5-year Shares Outstanding (Diluted Average) high stood at $41.5 million for Q2 2025, and its period low was $15154.0 during Q2 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $16.9 million, with a median of $18.1 million in 2023.
  • In the last 5 years, ProPhase Labs' Shares Outstanding (Diluted Average) tumbled by 9984.29% in 2021 and then skyrocketed by 13104839.04% in 2022.
  • Quarter analysis of 5 years shows ProPhase Labs' Shares Outstanding (Diluted Average) stood at $18.4 million in 2021, then increased by 1.4% to $18.7 million in 2022, then dropped by 7.74% to $17.2 million in 2023, then rose by 18.92% to $20.5 million in 2024, then surged by 103.01% to $41.5 million in 2025.
  • Its last three reported values are $41.5 million in Q3 2025, $41.5 million for Q2 2025, and $35.2 million during Q1 2025.